Related Experiment Video
Updated: Jun 12, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Ketamine for refractory depression: Save the best for last?
Kabir Nigam1, Franklin King2, Fernando Espi Forcen3
1Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.
None:
Ketamine has recently been shown to be non-inferior to electroconvulsive therapy (ECT), one of psychiatry's most effective treatments for depression. Given the novelty of ketamine as well as its interventional nature, ketamine is currently viewed as an alternative to ECT and as such, considered a third-line agent for treatment-refractory depression. However, available data suggest that ketamine carries a low side-effect burden and is better tolerated than many second-line augmentation strategies for depression. With this combination of higher efficacy and lower side-effect burden in conjunction with what is known about treatment outcomes in relation to the duration of untreated illness, it is in the best interest of patients for the field of psychiatry to evaluate ketamine as a second-line augmentation strategy for refractory depression.
More Related Videos
Related Concept Videos
Electroconvulsive Therapy
Parenteral Anesthetics: Overview
Psychosis: Goals of Pharmacotherapy
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

